Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.42 |
| ▸ | PGR | P06401 | 7/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891679 | 0.95 | AR (0.45) | ARPGRNR3C1CYP3A4POLB | |
| SCHEMBL6865376 | 0.95 | AR (0.45) | ARPGRNR3C1CYP3A4POLB | |
| SCHEMBL5891654 | 0.87 | AKR1C3 (0.34) | ARPGRNR3C1CYP3A4 | |
| SCHEMBL7868038 | 0.87 | AKR1C3 (0.34) | ARPGRNR3C1CYP3A4 | |
| SCHEMBL5891671 | 0.84 | AKR1C3 (0.33) | ARPGRNR3C1 | |
| SCHEMBL5892047 | 0.79 | AR (0.53) | ARPGRNR3C1CYP3A4MAPT | |
| SCHEMBL7871730 | 0.79 | AR (0.53) | ARPGRNR3C1CYP3A4MAPT | |
| SCHEMBL6864127 | 0.76 | AKR1C3 (0.33) | PGR | |
| SCHEMBL8410110 | 0.75 | PGR (0.36) | ARPGRNR3C1CYP3A4POLB | |
| SCHEMBL5891966 | 0.75 | PGR (0.36) | ARPGRNR3C1CYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148213-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
| US-6806263-B2 | NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS | SCHERING AG (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AG (DE) | 2003-07-17 | — | — | US | disclosed |
| US-6503895-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | US | disclosed |
| EP-0970103-B1 | ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN | SCHERING AG (DE) | 2002-04-17 | — | — | EP | disclosed |
| US-6316432-B1 | ANTIESTROGENS AND ANTIFERTILITY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, HSD3B1, CYP17A1 | AR 149/4885PGR 71/4885NR3C1 52/4885 |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, NR5A1, HSD3B1 | AR 186/4885PGR 52/4885NR3C1 31/4885 |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | NR5A1, HSD17B11, CYP21A2 | AR 126/4885PGR 40/4885NR3C1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.